Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Cross-Reactive Dengue Fully Human Monoclonal Antibodies

Posted Jan 10 2013 7:00pm

Description of Invention:
Among the arthropod-borne flaviviruses, the four dengue virus serotypes, dengue type 1 virus (DENV-1), dengue type 2 virus (DENV-2), dengue type 3 virus (DENV-3), and dengue type 4 virus (DENV-4) are most important in terms of human morbidity and geographic distribution. Dengue viruses cause dengue outbreaks and major epidemics in most tropical and subtropical areas where Aedes albopictus and Aedes aegypti mosquitoes are abundant.

A safe and effective vaccine against dengue is currently not available. Passive immunization with monoclonal antibodies from non-human primates or humans represents a possible alternative to vaccines for prevention of illness caused by dengue virus. This invention claims fully human monoclonal antibodies that bind and neutralize dengue type 1, 2, 3 and 4 viruses. It also claims fragments of such antibodies and nucleic acids encoding the antibodies of the invention as well as prophylactic, therapeutic and diagnostic methods employing the antibodies and nucleic acids of the invention.

Applications:
  • Prophylaxis/therapy against dengue serotypes 1, 2, 3, and 4.
  • Dengue diagnostics.


Advantages:
  • Antibodies are cross-reactive with all four serotypes of dengue.
  • Antibodies are fully human.


Development Status:
  • Pre-clinical
  • In vitro data


Inventors:
Dimiter S Dimitrov (NCI)
Zhongyu Zhu (NCI)


Patent Status:
HHS, Reference No. E-273-2011/0
US, Application No. 61/646,638 filed 14 May 2012


Related Technologies:
US, Patent No. 7,622,113, Issued 24 Nov 2009, Reference No. E-066-2003/5
US, Application No. 12/607,035 filed 27 Oct 2009, Reference No. E-066-2003/5
US, Application No. 13/692,521 filed 03 Dec 2012, Reference No. E-066-2003/5


Collaborative Research Opportunity:
The NCI/CCR/NP is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Cross-Reactive Dengue Fully Human Monoclonal A. For collaboration opportunities, please contact John Hewes, Ph.D. at hewesj@mail.nih.gov .


For Licensing Information Please Contact:
Peter Soukas J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 14,
Rockville, MD 20852-3804
United States
Email: soukasp@mail.nih.gov
Phone: 301-435-4646
Fax: 301-402-0220


Ref No: 2508

Updated: 01/2013

Post a comment
Write a comment:

Related Searches